Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090242 · ClinicalTrials.gov registry record · NA
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
A NA study, sponsored by Becton, Dickinson and Company.
- Terminated
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT04090242 is a NA study that was terminated before completion, run by Becton, Dickinson and Company. The registered enrollment target is 58 participants.
The verdict
NCT04090242, a NA study, was terminated before completion, sponsored by Becton, Dickinson and Company.
- TERMINATED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy. Subjects will be randomized to either receive the DC App and BD Nano 2nd Gen pen needles (intervention) or continue their standard of care using their current pen needle and diabetes management (control). The study will consist of four visits and two scheduled phone calls across a total of 10 weeks.
Interventions
- DEVICE BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2020-06-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04090242
The ClinicalTrials.gov registry entry for NCT04090242 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle is the first listed.
NCT04090242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04090242 about?
NCT04090242 is a clinical study titled "Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes". This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy. Subjects will be randomized to either receive the DC App and BD Nano 2nd Gen pen needles (intervention) or continue their standard of...
What is the current status of trial NCT04090242?
This trial is currently terminated. It is a NA study. The enrollment target is 58 participants. The study started on 2019-09-06. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT04090242?
The interventions under investigation include: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle (DEVICE).
Who is sponsoring clinical trial NCT04090242?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.